6-K ·Filed Sep 30, 2026
Notable filing: 6-K
Actionable Insight • Neutral
This is a routine annual governance filing with no market-moving information. Monitor the company's Annual Report for financial results and pipeline updates, which are referenced but not included in this filing.
Latest settled — T+5d
RADX ▼ -29.01% at T+5d
NEUTRAL call -29.01% · α vs SPY -30.93% · entry $1.62 → $1.15
Latest observation: T+17 -9.27% FF3 residual α
T+1d
-8.64%
call -8.64% · α -8.82%
$1.48
settled 25d ago
T+5d
-29.01%
call -29.01% · α -30.93%
$1.15
settled 19d ago
T+20d
Pending
tomorrow
T+60d
Pending
in 8w
Price Chart
Loading chart...
Executive Summary
Radiopharm Theranostics filed its annual Appendix 4G and Corporate Governance Statement for the year ended 30 June 2026, confirming compliance with ASX Corporate Governance Council recommendations. The filing is a routine governance disclosure with no material financial or operational data disclosed.
Key Facts
- Financial year ended 30 June 2026 Corporate Governance Statement approved by the board as at 22 September 2026 and lodged with ASX on 30 September 2026. Board consists of 6 directors (5 independent and 3 independent directors. The Chairman Mr Paul Hopper is a non-independent director. The company has no internal audit function and does not consider it appropriate at this stage in its development.
- Gender diversity at 30 June 2026: 6 directors (5 men (83% men) 1 woman (17% women) 1 senior executive (1 senior executive (100% men) 13 employees (5 men (38% women) 8 women (62%) Whole organisation 20 (11 men (55% women) 9 women (45%). The company is below the threshold of 100 employees for reporting under the Workplace Gender Equality Act 2012.
- The company was not in the S&P All Ordinaries Index or S&P ASX 300 Index at the start of the financial year and was therefore not required to have an audit committee or remuneration committee under ASX Listing Rules.
- A summary of material business risks faced by the company is included in the Directors Report within the Annual Report.
- No financial data (revenue, earnings, cash flow, debt) is disclosed in this filing.
Financial Impact
No financial figures disclosed in this filing.
Risk Factors
- No material risks disclosed in this filing; refer to the Directors Report for a summary of material business risks in the Annual Report.
- The company does not have an internal audit function, which may increase the effectiveness of its risk management and internal control processes.
- The Chairman is not independent director, which may not align with ASX recommendations for some investors.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-104850 |
| Document: ea0307187-6k_radiopharm.htm | 0001213900-26-104850 |
| Document: 0001213900-26-104850-index-headers.html | 0001213900-26-104850 |
| Document: 0001213900-26-104850-index.html | 0001213900-26-104850 |
| Document: 0001213900-26-104850.txt | 0001213900-26-104850 |
32 reports for RADX
69% Hit rate @ T+5 Went positive at some point 11 of 16 best @ T+60▲ +73.69%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
Showing 10 of 32
US Market Status
Market Open — Closes in 2m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers